Central Retinal or Hemiretinal Vein Occlusion
- Comino Study is a phase III trial. This Study will Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion(Genentech/Roche)
Symptomatic Epiretinal Membrane
- Protocol AM with the Diabetic Retinopathy Clinical Research Network. This Study is a Phase III trial Randomized Trial Comparing Immediate vs. Deferred Surgery for Symptomatic Epiretinal Membrane or ERM (DRCR Network)
Diabetic Macular Edema
- Pagoda Study is a Phase III trial This Study Will Evaluate the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Participants With Diabetic Macular Edema Compared With Intravitreal Ranibizumab (Genentech/Roche)
- Rhone X is a Phase III Trial. This Study Evaluates the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema (Genentech/Roche)
Completed Clinical Trials
Age-Related Macular Degeneration
- RE-VIEW: Phase IV, Aflibercept injections in subjects for the treatment of neovascular age-related macular degeneration.
- HARBOR: Phase III, Ranibizumab injections in subjects with subfoveal neovascular age related macular degeneration.
- DENALI: Phase IIIB, Verteporfin photodynamic therapy administered in conjunction with ranibizumab in subjects with choroidal neovascularization secondary to age-related macular degeneration.
- VIEW 1: Phase III, VEGF-Trap injections in subjects with neovascular age related macular degeneration.
- SAILOR: Phase IIIb, Ranibizumab injections in subjects with macular edema secondary to age-related macular degeneration.
- PIER: Phase IIIb, Ranibizumab injections with subfoveal choroidal neovascularization with or without classic CNV secondary to age-related macular degeneration.
- LUCERNE: A Study to Evaluate the Efficacy and Safety of Faricimabin Participants With Neovascular Age-Related Macular Degeneration. This study will evaluate the efficacy, safety, durability, and pharmacokinetics of Faricimab administered at intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with neovascular age-related macular degeneration (nAMD).
- MERLIN: Study of Safety and Efficacy of Brolucizumab 6mg Dosed Every 4 Weeks Compared to Aflibercept 2mg Dosed Every 4 Weeks in Patients with Retinal Fluid Despite Frequent Anti-VEGF Injections.
- VISTA: Phase III, VEGF-Trap injections/laser in subjects for the treatment of diabetic macular edema.
- IDEAL: Phase II, iCO-007 as monotherapy or in combination with Ranibizumab or laser for the treatment of diabetic macular edema.
- READ3: Phase III, Ranibizumab for the treatment of diabetic macular edema with high dose.
- RIDE: Phase III, Ranibizumab injections in subjects with clinically significant macular edema secondary to diabetes.